Eli Lilly cuts hospitals' 340B pricing over data policy dispute
Eli Lilly is cutting 340B drug pricing to hospitals that fail to comply with its claims data policy.
Eli Lilly and Company
Eli Lilly and Company is a major global pharmaceutical company with a broad portfolio spanning diabetes/obesity, oncology, neuroscience, immunology, and rare diseases. Its GLP-1 franchise (Mounjaro/tirzepatide, Zepbound) and the oral GLP-1 candidate orforglipron are reshaping obesity care. Lilly has been the most aggressive large-pharma dealmaker of the past decade, completing more biotech buyouts than any other top-12 pharma by revenue, with 10 acquisitions in 2026 alone accounting for roughly half of pharma's total M&A capacity (~$25B+ committed).
Company Info
Sector: Pharmaceutical / Therapeutics
Headquarters: Indianapolis, Indiana, USA
Founded: 1876
Website: www.lilly.com/
Upcoming Milestones & Key Dates
Mid-2026
Launch
Commercial launch of Foundayo (orforglipron) for weight management and diabetes
Late 2026
Earnings
Q3 2026 Earnings — tirzepatide franchise growth and pipeline update
Q4 2026
Business Development
Q3 2026 M&A integration update — 10 biotech acquisitions completed in 2026 (~$25B+ spent)
Clinical Development Pipeline
Mounjaro / Zepbound (tirzepatide)
Target: Dual GIP/GLP-1 receptor agonistOrforglipron (Foundayo)
Target: Oral non-peptide GLP-1 receptor agonistDonanemab
Target: Anti-amyloid beta p3-42 antibody (modified)Recent News
Exclusive: Lilly's TuneLab crosses 100-member mark, adds AI models from buzzy startup Chai
Lilly's TuneLab AI platform has crossed the 100-member mark and added AI models from Chai.
Lilly's $2.3B Ajax Drug Works 'Right Out of the Gate' in First Clinical Data
Eli Lilly's lead asset from its $2.3B acquisition of Ajax Therapeutics, a JAK2 inhibitor, showed 'started working right out of the gate, with a good safety profile' in early clinical data, validating the deal thesis.
ADA: Lilly Bests Novo Again, Takes GLP-1 Pill Foundayo to FDA for Diabetes Approval
Eli Lilly has submitted Foundayo, its oral GLP-1 receptor agonist, to the FDA for diabetes approval on the strength of head-to-head Phase 3 data presented at ADA showing superior A1C reduction versus Novo Nordisk's Wegovy pill.
ADA: Lilly Sets 'New Record in Weight Loss Olympics' With Next-Gen Asset
Eli Lilly's next-generation obesity candidate produced a 'new record' weight reduction in a Phase 2 readout at ADA, extending Lilly's lead in the highly competitive injectable obesity space.
Eli Lilly Invests in Startup Abridge for Clinical Trial Recruitment
Eli Lilly has made a strategic investment in Abridge, the AI medical scribe company, to accelerate clinical trial recruitment and reduce site burden, deepening the pharma's footprint in generative AI healthcare tools.
Lilly Gives Hospitals Deadline to Comply With 340B Claims Data Policy
Eli Lilly has given hospitals a five-day deadline to comply with the company's new 340B claims data policy or risk losing 340B drug pricing on key products, escalating the fight over federal drug discount program transparency.
Lilly's $25B+ M&A Spree Captures Half of Pharma's 2026 Capacity
Eli Lilly's $25B+ in biotech acquisitions through 2026 represents roughly half of total pharma M&A spending in the year, underscoring the company's aggressive dealmaking to refill its pipeline as GLP-1 sales surge.
Leadership Team
Careers & Job Openings